Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 251

1.

Benefits and risks of skin cancer screening.

Breitbart EW, Choudhury K, Anders MP, Volkmer B, Greinert R, Katalinic A, Tacke J, Keilholz U.

Oncol Res Treat. 2014;37 Suppl 3:38-47. doi: 10.1159/000364887. Epub 2014 Aug 29. No abstract available.

PMID:
25195831
[PubMed - in process]
2.

Personalized medicine approaches for colon cancer driven by genomics and systems biology: OncoTrack.

Henderson D, Ogilvie LA, Hoyle N, Keilholz U, Lange B, Lehrach H, OncoTrack Consortium.

Biotechnol J. 2014 Sep;9(9):1104-14. doi: 10.1002/biot.201400109. Epub 2014 Jul 29.

PMID:
25074435
[PubMed - in process]
3.

Detection of circulating tumor cells for prediction of recurrence after adjuvant chemoradiation in locally advanced squamous cell carcinoma of the head and neck.

Tinhofer I, Konschak R, Stromberger C, Raguse JD, Dreyer JH, Jöhrens K, Keilholz U, Budach V.

Ann Oncol. 2014 Jul 23. pii: mdu271. [Epub ahead of print]

PMID:
25057171
[PubMed - as supplied by publisher]
4.

Circulating tumor cells as tumor biomarkers in melanoma: detection methods and clinical relevance.

Khoja L, Lorigan P, Dive C, Keilholz U, Fusi A.

Ann Oncol. 2014 Jun 6. pii: mdu207. [Epub ahead of print] Review.

PMID:
24907634
[PubMed - as supplied by publisher]
5.

Expression and activity of EGFR in human cutaneous melanoma cell lines and influence of vemurafenib on the EGFR pathway.

Gross A, Niemetz-Rahn A, Nonnenmacher A, Tucholski J, Keilholz U, Fusi A.

Target Oncol. 2014 May 15. [Epub ahead of print]

PMID:
24824730
[PubMed - as supplied by publisher]
6.

Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part).

Vermorken JB, Peyrade F, Krauss J, Mesía R, Remenar E, Gauler TC, Keilholz U, Delord JP, Schafhausen P, Erfán J, Brümmendorf TH, Iglesias L, Bethe U, Hicking C, Clement PM.

Ann Oncol. 2014 Mar;25(3):682-8. doi: 10.1093/annonc/mdu003.

PMID:
24567516
[PubMed - in process]
Free PMC Article
7.

Long-term structured follow-up is essential after curative cancer treatment.

Keilholz U, Pezzutto A, Budach V, Eggert A.

Dtsch Arztebl Int. 2014 Jan 6;111(1-2):1-2. doi: 10.3238/arztebl.2014.0001. No abstract available.

PMID:
24565269
[PubMed - in process]
Free PMC Article
8.

Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial.

Leyvraz S, Piperno-Neumann S, Suciu S, Baurain JF, Zdzienicki M, Testori A, Marshall E, Scheulen M, Jouary T, Negrier S, Vermorken JB, Kaempgen E, Durando X, Schadendorf D, Gurunath RK, Keilholz U.

Ann Oncol. 2014 Mar;25(3):742-6. doi: 10.1093/annonc/mdt585. Epub 2014 Feb 7.

PMID:
24510314
[PubMed - in process]
9.

[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].

Miller K, Bergmann L, Gschwend J, Keilholz U, Kuczyk M.

Aktuelle Urol. 2014 Jan;45(1):39-44. doi: 10.1055/s-0033-1363228. Epub 2014 Feb 5. German.

PMID:
24500960
[PubMed - in process]
10.

Cancer stem cell characteristics of circulating tumor cells.

Tinhofer I, Saki M, Niehr F, Keilholz U, Budach V.

Int J Radiat Biol. 2014 Aug;90(8):622-7. doi: 10.3109/09553002.2014.886798. Epub 2014 May 12.

PMID:
24460132
[PubMed - in process]
11.

PI3K/PTEN/AKT/mTOR pathway genetic variations are associated with the clinical outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.

Pfisterer K, Fusi A, Klinghammer K, Knödler M, Nonnenmacher A, Keilholz U.

Head Neck. 2014 Jan 13. doi: 10.1002/hed.23604. [Epub ahead of print]

PMID:
24421178
[PubMed - as supplied by publisher]
12.

[Diagnosis of and therapy for choroidal melanoma].

Lipski AC, Lakotka N, Riechardt AI, Willerding GD, Heufelder J, Türkmen S, Keilholz U, Moser L, Joussen AM.

Klin Monbl Augenheilkd. 2013 Oct;230(10):1005-19. doi: 10.1055/s-0033-1350833. Epub 2013 Sep 17. Review. German.

PMID:
24046188
[PubMed - indexed for MEDLINE]
13.

Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma.

Kruit WH, Suciu S, Dreno B, Mortier L, Robert C, Chiarion-Sileni V, Maio M, Testori A, Dorval T, Grob JJ, Becker JC, Spatz A, Eggermont AM, Louahed J, Lehmann FF, Brichard VG, Keilholz U.

J Clin Oncol. 2013 Jul 1;31(19):2413-20. doi: 10.1200/JCO.2012.43.7111. Epub 2013 May 28.

PMID:
23715572
[PubMed - indexed for MEDLINE]
Free Article
14.

Sex is an independent prognostic indicator for survival and relapse/progression-free survival in metastasized stage III to IV melanoma: a pooled analysis of five European organisation for research and treatment of cancer randomized controlled trials.

Joosse A, Collette S, Suciu S, Nijsten T, Patel PM, Keilholz U, Eggermont AM, Coebergh JW, de Vries E.

J Clin Oncol. 2013 Jun 20;31(18):2337-46. doi: 10.1200/JCO.2012.44.5031. Epub 2013 May 20.

PMID:
23690423
[PubMed - indexed for MEDLINE]
Free Article
15.

Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study).

Busse A, Rapion J, Fusi A, Suciu S, Nonnenmacher A, Santinami M, Kruit WH, Testori A, Punt CJ, Dalgleish AG, Spatz A, Eggermont AM, Keilholz U.

Cancer Immunol Immunother. 2013 Jul;62(7):1223-33. doi: 10.1007/s00262-013-1428-4. Epub 2013 Apr 27.

PMID:
23624802
[PubMed - indexed for MEDLINE]
16.

Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors.

Tjulandin S, Moiseyenko V, Semiglazov V, Manikhas G, Learoyd M, Saunders A, Stuart M, Keilholz U.

Invest New Drugs. 2014 Feb;32(1):145-53. doi: 10.1007/s10637-013-9963-6. Epub 2013 Apr 16.

PMID:
23589215
[PubMed - in process]
17.

Characterization of small spheres derived from various solid tumor cell lines: are they suitable targets for T cells?

Busse A, Letsch A, Fusi A, Nonnenmacher A, Stather D, Ochsenreither S, Regenbrecht CR, Keilholz U.

Clin Exp Metastasis. 2013 Aug;30(6):781-91. doi: 10.1007/s10585-013-9578-5. Epub 2013 Mar 22.

PMID:
23519726
[PubMed - indexed for MEDLINE]
18.

Phase II study of cetuximab in combination with docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after platinum-containing therapy: a multicenter study of the Arbeitsgemeinschaft Internistische Onkologie.

Knoedler M, Gauler TC, Gruenwald V, Matzdorff A, Schroeder M, Dietz A, Jordan WO, Arnold D, Hennemann B, Hofele C, Weissinger F, Eberhardt W, Keilholz U.

Oncology. 2013;84(5):284-9. doi: 10.1159/000345453. Epub 2013 Feb 26.

PMID:
23445718
[PubMed - indexed for MEDLINE]
19.

Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.

Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE; ANAHYDRET Study Group.

Blood. 2013 Mar 7;121(10):1720-8. doi: 10.1182/blood-2012-07-443770. Epub 2013 Jan 11.

PMID:
23315161
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Dummer R, Hauschild A, Guggenheim M, Keilholz U, Pentheroudakis G; ESMO Guidelines Working Group.

Ann Oncol. 2012 Oct;23 Suppl 7:vii86-91. No abstract available.

PMID:
22997461
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk